Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

被引:0
|
作者
G. Quintero-Aldana
M. Jorge
C. Grande
M. Salgado
E. Gallardo
S. Varela
C. López
M. J. Villanueva
A. Fernández
E. Alvarez
P. González
J. Castellanos
J. Casal
R. López
B. Campos Balea
机构
[1] Hospital Universitario Lucus,
[2] Augusti,undefined
[3] Complejo Hospitalario Universitario de Vigo,undefined
[4] CHUVI,undefined
[5] Complejo Hospitalario de Ourense,undefined
[6] CHOU,undefined
[7] Complejo Hospitalario Universitario de Santiago,undefined
[8] CHUS,undefined
来源
关键词
Advanced gastric cancer; Cisplatin; Combination chemotherapy; Docetaxel;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:731 / 737
页数:6
相关论文
共 50 条
  • [21] Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer
    Keon Woo Park
    Jin Seok Ahn
    Young Suk Park
    Jeeyun Lee
    Jung Hoon Kang
    Joon Oh Park
    Ho Yeong Lim
    Young-Hyuck Im
    Won Ki Kang
    Keunchil Park
    Soon Il Lee
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 17 - 21
  • [22] A PHASE II STUDY WITH CAPECITABINE AND CISPLATIN AS FIRST-LINE THERAPY IN ADVANCED GASTRIC CANCER
    Fonseca, P. J.
    Vieitez, J. M.
    Frunza, M.
    Berros, J. P.
    Fernandez De Sanmamed, M.
    Muriel, C.
    Izquierdo, M.
    Pardo, P.
    Gutierrez, E.
    Lacave, A. J.
    ANNALS OF ONCOLOGY, 2010, 21 : 240 - 240
  • [23] CISPLATIN AND DOCETAXEL AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Marrupe, D.
    Garcia, S.
    Lopez, E.
    Mendez, M.
    Quiben, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 112 - 113
  • [24] A phase I/II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer.
    Kang, YK
    Kim, TW
    Chang, HM
    Ryu, MH
    Yook, JH
    Oh, ST
    Kim, BS
    Lee, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 329S - 329S
  • [25] Modified Docetaxel-cisplatin in Combination with Capecitabine as First-line Treatment in Metastatic Gastric Cancer. A Phase II Study
    Polyzos, Aristides
    Felekouras, Evangellos
    Karatzas, Theodore
    Griniatsos, John
    Dimitroulis, Dimitrios
    Polyzos, Kostas
    Kontzoglou, Kostas
    Mantas, Dimitrios
    Karavokyros, John
    Nikiteas, Nikolaos
    Tsavaris, Nikolas
    Syrigos, Kostas
    Vafiadis, Irene
    ANTICANCER RESEARCH, 2012, 32 (09) : 4151 - 4156
  • [26] A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma
    Rougier, P
    Adenis, A
    Ducreux, M
    de Forni, M
    Bonneterre, J
    Dembak, M
    Clouet, P
    Lebecq, A
    Baille, P
    Lefresne-Soulas, F
    Blanc, C
    Armand, JP
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (08) : 1016 - 1025
  • [27] A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
    Kim, Young Saing
    Sym, Sun Jin
    Park, Se Hoon
    Park, Inkeun
    Hong, Junshik
    Ahn, Hee Kyung
    Park, Jinny
    Cho, Eun Kyung
    Lee, Woon Ki
    Chung, Min
    Lee, Jae Hoon
    Shin, Dong Bok
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 163 - 169
  • [28] A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
    Young Saing Kim
    Sun Jin Sym
    Se Hoon Park
    Inkeun Park
    Junshik Hong
    Hee Kyung Ahn
    Jinny Park
    Eun Kyung Cho
    Woon Ki Lee
    Min Chung
    Jae Hoon Lee
    Dong Bok Shin
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 163 - 169
  • [29] A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China
    Xiao, Cheng
    Qian, Jiong
    Zheng, Yulong
    Song, Fang
    Wang, Qiangfeng
    Jiang, Haiping
    Mao, Chenyu
    Xu, Nong
    MEDICINE, 2019, 98 (20)
  • [30] Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer
    Kim, TW
    Chang, HM
    Kang, HJ
    Lee, JR
    Ryu, MH
    Ahn, JH
    Kim, JH
    Lee, JS
    Kang, YK
    ANNALS OF ONCOLOGY, 2003, 14 (07) : 1115 - 1120